Incidence of atypical femoral fractures in the treatment of bone metastasis: An alert report

Incidence of atypical femoral fractures in the treatment of bone metastasis: An alert report

Background: As the life expectancy of cancer-bearing patients has increased, more patients with bone metastasis are receiving long-term treatment with bone-modifying agents (BMAs; e.g., zoledronate and denosumab), which are a risk factor for developing atypical femoral fracture (AFF). In this study,...

Full description

Bibliographic Details
Main Authors: Takumi Kaku, Yoto Oh, Shingo Sato, Hirotaka Koyanagi, Takashi Hirai, Masato Yuasa, Toshitaka Yoshii, Tsuyoshi Nakagawa, Satoshi Miyake, Atsushi Okawa
Format: Article
Language:English
Published: Elsevier 2020-08-01
Series:Journal of Bone Oncology
Subjects:
Atypical femoral fracture
Bone metastasis
Bone-modifying agent
Denosumab
Bisphosphonate
Skeletal-related event
Online Access:http://www.sciencedirect.com/science/article/pii/S2212137420300567

Internet

http://www.sciencedirect.com/science/article/pii/S2212137420300567

Similar Items